US FDA Continues Cannabinoid Analysis Required In FY2021 Budget

The US Food and Drug Administration continues testing, which Congress funded in its current budget, to find disparities between labeled cannabinoid levels and the amounts in products as momentum builds on Capitol Hill behind legislation that would direct the agency to make lawful the ingredients’ use in dietary supplements.

Doug Stearn, regulatory affairs deputy director at the FDA’s Center for Food Safety and Applied Nutrition, says while the agency’s analysis of cannabinoid products “is still developing” since it received $5m from Congress for